We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Draft Guidance Tackles Early-Stage CGT Product Development
Draft Guidance Tackles Early-Stage CGT Product Development
July 12, 2013
Patients with severe or advanced disease may not be ideal candidates in early-stage clinical trials to develop cellular and gene therapy (CGT) products, according to an FDA draft guidance.